What are the main MaxLiving franchise pros and cons?
MaxLiving’s clearest verified advantage is a defined clinic system with extensive new-operator training, site assistance, operating standards, and a broad 2024 Item 19 reporting population. Its clearest burden is the combination of licensed on-premises supervision, potentially six months of training, fixed monthly payments, and substantial franchisor control. These 2025 FDD trade-offs are conditional, not a buy-or-reject recommendation.
Data basis. This analysis uses the Franchise Disclosure Document issued October 14, 2025 by Maximized Living Health Centers, LLC for one-site Franchise Clinics, including the Existing Clinic Conversion Incentive, Legacy Clinic Incentive, and 2025/2026 Renewal Incentive addenda. Contract facts come from Items 1, 5–12, 15–17, 19–22 and Exhibit A. Item 19 reports 2023–2024 data; Item 20 reports 2022–2024 outlet activity. Research was checked July 27, 2026.
The current official MaxLiving franchise page describes hands-on training and the 5 Essentials program. The official company overview, clinic finder, professional events page, and the FTC franchise buyer guide provide supplemental context. No matching public FDD on a franchise-controlled domain was verified, so FDD citations below are unlinked.
Which MaxLiving obligations create the clearest buyer trade-offs?
The most consequential factors are not separate “good” and “bad” lists. Each MaxLiving feature changes the buyer outcome according to clinical credentials, available time, capital structure, tolerance for system control, and intended exit path.
Initial training and licensed supervision
Limited territory and reserved channels
Item 19 revenue and patient-volume evidence
Approved suppliers, Max 3, and the Computer System
Fixed royalty and Marketing Fund obligations
Franchise Clinic and License Program transition
Renewal, transfer, and exit conditions
Buyer-verification questions before signing
- Which individual will be the Operating Principal and Head Licensed Practitioner, and how will six months of training affect existing income and staffing?
- What exact Territory map will apply after site acceptance, and which current MaxLiving, License Program, e-commerce, or differently branded activities can reach the same patients?
- Which 16 Franchise Clinics were outside the 2024 Item 19 reporting group, and why were their records excluded?
- What were the 2024 clinic-level expenses, owner compensation, patient mix, and insurance reimbursement percentages for comparable markets?
- Which purchases must come from Max 3 or other Approved Suppliers, and what technology upgrades, maintenance plans, or data-access terms are currently expected?
- How were the 20 reported 2024 terminations distributed between Franchise Agreements and License Program agreements, and what reasons appear in former-operator interviews?
- What renewal upgrades, release language, transfer conditions, financing payoff obligations, and state-law modifications would apply to the buyer’s planned exit?
The current official franchise page advertises 400-plus weekly patients and income relative to a national chiropractic average. The 2025 FDD instead reports a 2024 average of 319 weekly visits across 77 clinics and does not present that national benchmark. Request written substantiation and any compliant supplemental Item 19 disclosure before using the web claims in a forecast.
What does MaxLiving’s outlet history show?
Item 20 shows a three-year decline in the combined Franchise Clinic and License Program population. That direction is material for diligence, but the mixed contract population means the chart cannot identify clinic economics, franchisee satisfaction, or the cause of each departure.
Interpretation: the combined population decreased by 23 outlets, or 12.0%, over two years; the FDD reports 23 openings and 17 terminations in 2022, 11 openings and 18 terminations plus one other cessation in 2023, and eight openings with 20 terminations in 2024.
Source: 2025 FDD, Item 20, Tables 1 and 3, pp. 43–47. “Franchised” combines Franchise Clinics and License Program locations.
The License Program stopped accepting new agreements in July 2025, while some licensees could continue through their existing terms or convert to the Franchise Agreement. Ask MLHC to reconcile the current count by agreement type; a combined Item 20 trend is not a unit-success measure.
How useful is MaxLiving’s Item 19 disclosure?
The 2024 reporting group is comparatively broad and includes exact averages, medians, ranges, patient visits, and the number above average. Its usefulness stops at Gross Sales and visits: the disclosure is unaudited, omits expenses and owner compensation, and excludes legacy License Program locations.
The included clinics were open for all 12 months of 2024, remained under one continuous franchisee owner or ownership group, and provided the required reporting.
Interpretation: high population coverage improves transparency, but selection rules still exclude clinics without the required operating period, ownership continuity, or reporting.
Source: 2025 FDD, Item 19, pp. 38–42. Calculation: 77 ÷ 93 = 82.8%; excluded group = 93 − 77 = 16, or 17.2%.
Item 19 reports 2024 average Gross Sales of $908,947 and median Gross Sales of $678,008, with only 35% of reporting clinics at or above the average. The gap between average and median, plus a $90,700 to $4,235,940 range, makes the median, market match, expense structure, and clinic maturity more decision-useful than the average alone.
Where does MaxLiving provide structure, and where does the buyer remain accountable?
MaxLiving defines the operating framework, but the franchisee and licensed professionals retain major legal, clinical, staffing, lease, and local-execution responsibilities. Buyers who equate system standards with outsourced clinic management would misread the Franchise Agreement.
System defined by MLHC
- Site acceptance and approved real-estate vendor process
- Initial Training, Operations Manual, and updated System standards
- Approved Suppliers, Max 3 products, and Computer System specifications
- Marketing Fund direction, authorized advertising, and integrated web platform
Responsibility retained by the operator
- Chiropractic licensure, entity structure, HIPAA, and healthcare-law compliance
- Independent clinical judgment and patient-care decisions
- Hiring, payroll, supervision, and employee performance
- Lease, buildout, equipment, insurance, permits, and third-party contracts
Source: 2025 FDD, Items 1, 7–8, 11, 15–16 and Franchise Agreement Parts D and E. The official consumer services page describes the patient-facing care categories, while the FDD controls the operator’s obligations.
Which buyer profiles may align with MaxLiving, and which may face friction?
Fit depends less on the number of listed advantages than on whether the buyer can satisfy the clinical, time, capital, control, and Franchise Agreement requirements simultaneously.
Potentially aligned profile
A licensed chiropractor, or qualified ownership group with a committed Head Licensed Practitioner, may value a prescribed clinic format, long initial training, centralized web and marketing infrastructure, named operating standards, and a 10-year planning horizon. Alignment is stronger when the buyer has sufficient liquidity beyond the three-month Item 7 allowance and accepts active on-premises supervision.
Profile likely to experience friction
An absentee investor, rapid-launch buyer, operator seeking broad product or digital discretion, or owner expecting protected online demand may face structural conflict. Friction also rises for buyers who need a short or unilateral exit, depend on proportionate local Marketing Fund spending, or cannot absorb fixed monthly fees and technology changes during low-sales periods.
What is the due-diligence conclusion?
MaxLiving’s strongest verified structural advantage is its defined Franchise Clinic system: 680 hours of new-clinic training, site and operating procedures, approved technology, and an Item 19 population covering 77 of 93 eligible clinics. The most material burden is the active licensed-supervision model combined with fixed payments, supplier and technology dependence, narrow territory protection, and consent-based renewal or exit.
The model may align with a licensed, hands-on clinic operator who wants prescribed systems and can fund a lengthy launch. It is more likely to create friction for an absentee or autonomy-focused buyer. The highest-priority pre-signing verification is a clinic-level reconciliation of Item 19 economics and Item 20 departures for comparable markets, agreement types, and ownership profiles.